Patents by Inventor Robert D. Radcliffe

Robert D. Radcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5196510
    Abstract: A system or method for identifying and/or designing novel peptides and polypeptides comprising an amino acid sequence which mimics the molecular recognition site of either (a) a macromolecule such as an immunoglobulin, an enzyme, a receptor protein, a lectin or other binding protein or (b) a small molecule or a small region of a large molecule which functions as a ligand and is recognized and binds specifically to a macromolecule is disclosed. Novel peptides and polypeptides as well as conjugates of the peptides and polypeptides are also disclosed. Applications for use of the peptides, polypeptides and conjugates in a wide range of fields such as biomedicine; biological control and pest regulation; agriculture; cosmetics; environmental control and waste management; chemistry; catalysis; nutrition and food industries; military uses; climate control, etc. are disclosed.
    Type: Grant
    Filed: May 7, 1990
    Date of Patent: March 23, 1993
    Assignee: Cytogen Corporation
    Inventors: John D. Rodwell, Thomas J. McKearn, Vernon L. Alvarez, Robert D. Radcliffe
  • Patent number: 5162512
    Abstract: Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: November 10, 1992
    Assignee: Cytogen Corporation
    Inventors: H. Dalton King, Anthony D. Lopes, Robert D. Radcliffe, John D. Rodwell, Daniel J. Coughlin
  • Patent number: 4950738
    Abstract: Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracyline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.
    Type: Grant
    Filed: June 5, 1987
    Date of Patent: August 21, 1990
    Assignee: Cytogen Corporation
    Inventors: H. Dalton King, Anthony D. Lopes, Robert D. Radcliffe, John D. Rodwell, Daniel J. Coughlin